February, 2012 - United States Patent & Trademark Office issues patent covering the inventive technology in the DermX, ProDermaCel and OralX product formulations.
March, 2011 - ProCertus BioPharm, Inc. closes $1.77 million Series A Financing led by Novartis Venture Fund, Venture Investors, LLC and the Wisconsin Alumni Research Foundation.
February, 2011 - Clinicians at the University of Wisconsin Carbone Cancer Center begin patient enrollment in a Phase I/II clinical trial to determine the safety and efficacy in radiodermatitis prevention of topically applied DermX vasoconstrictor in post-surgical breast cancer patients receiving 50-60 Gy radiotherapy course to prevent cancer.
February, 2011 - Second Phase I study is completed at the University of Wisconsin Carbone Cancer Center. DermX applied to patients receiving radiotherapy to treat bone metastasis demonstrated: i) no blood pressure elevations or significant adverse events, ii) no significant topical or systemic toxicities, and iii) successful compliance with the topical drug application schedule.
June 29, 2009 - Milwaukee Journal Sentinel interviews acting CEO (Paul Weiss) about opened clinical trials and ProCertus product development.
June 30, 2009 - ProCertus BioPharm, Inc. closes $1.05 Million Series A Financing led by Novartis Venture Fund and Venture Investors, LLC.
May, 2008 - Investigators (Dr. James Cleary et al.) at University of Wisconsin Carbone Cancer Center complete first Phase I clinical study of DermX/ProDermaCel technology. Normal subjects receiving six week topical application of DermX formulation demonstrated: i) no significant topical or systemic toxicities over the six week drug course at any of the scheduled doses, ii) successful compliance with the topical drug application schedule that involved five applications per week x six weeks, and iii) successful induction of the scored skin endpoint that predicted complete radioprotection in animal models of radiodermatitis.
May 10, 2007 - ProCertus BioPharm, Inc. closes $2.3 Million Series A Financing Led by Venture Investors LLC.